




Second Edition

CLINICAL CHEMISTRY, IMMUNOLOGY AND LABORATORY QUALITY CONTROL

*A Comprehensive Review for Board Preparation,
Certification and Clinical Practice*



**Amitava Dasgupta
and Amer Wahed**

Contents

PREFACE.....	XIX
CHAPTER 1	Instrumentation and analytical methods..... 1
	Instrumentation and analytical methods: An introduction..... 1
	Spectrophotometry and related techniques..... 1
	Atomic absorption..... 4
	Enzymatic assays..... 5
	Immunoassays..... 6
	Turbidimetry and nephelometry: Methods based on light scattering..... 6
	Ion selective electrodes..... 7
	Basic principles of chromatography..... 8
	Gas chromatography..... 10
	High-performance liquid chromatography..... 11
	Mass spectrometer as a detector..... 14
	Examples of application of chromatographic techniques in clinical toxicology laboratories..... 17
	Automation in clinical laboratory..... 19
	Electrophoresis including capillary electrophoresis..... 20
	Summary/key points..... 20
	References..... 23
CHAPTER 2	Immunoassay design and issues of interferences..... 25
	Application of immunoassays for various analytes..... 25
	Immunoassay design and principle..... 26
	Various commercially available immunoassays..... 29
	Heterogenous immunoassays..... 32
	Calibration of an immunoassay..... 33
	Various sources of interferences in immunoassays..... 33
	Interferences from bilirubin, hemolysis, and high lipid content..... 34

	Interferences from the endogenous and exogenous components.....	35
	Interferences of heterophilic antibodies in immunoassays.....	36
	Rheumatoid factor interferences.....	39
	Interferences from autoantibodies.....	39
	Macroenzyme interferences.....	40
	Other macroanalytes.....	42
	Prozone (or "hook") effect.....	42
	Summary/key points.....	42
	References.....	44
CHAPTER 3	Preanalytical variables.....	47
	Laboratory errors.....	47
	Order of draw of blood collection tubes.....	49
	Errors in patient preparation.....	50
	Biological rhythm and time for specimen collection.....	50
	Errors with patient identification and related errors.....	51
	Error of collecting blood in wrong tubes: Effect of anticoagulants.....	53
	Blood collection from catheter and intravenous line.....	54
	Issues with collecting urine specimens.....	54
	Issues with specimen processing and transportation.....	55
	Special issues: Blood gas and ionized calcium analysis.....	55
	Summary/key points.....	56
	References.....	57
CHAPTER 4	Laboratory statistics and quality control.....	59
	Mean, standard deviation, and coefficient of variation.....	59
	Precision and accuracy.....	60
	Gaussian distribution and reference range.....	60
	Sensitivity, specificity, and predictive value.....	62
	Random and systematic errors in measurements.....	63
	Laboratory quality control: Internal and external.....	63
	CAP proficiency testing.....	64
	Passing CAP proficiency testing.....	66
	What action to take if a laboratory failed CAP survey for certain analytes?.....	68
	Levey-Jennings chart and Westgard rules.....	68
	Delta checks.....	72
	Method validation for a new test using existing analyzer.....	73
	How to interpret regression equation?.....	74
	Bland-Altman plot.....	75
	How to implement a new analyzer in the laboratory?.....	75

	Pregnancy-associated plasma protein A.....	166
	Summary/key points.....	166
	References.....	170
CHAPTER 9	Endocrinology.....	173
	Introduction to various endocrine glands.....	173
	Hypothalamus.....	175
	Pituitary gland.....	177
	Thyroid gland.....	179
	Thyroid function tests.....	180
	Hypothyroidism.....	182
	Hyperthyroidism.....	184
	Disorders of parathyroid glands.....	185
	Adrenal glands.....	187
	Cushing's syndrome.....	189
	Conn's syndrome.....	190
	Hypoadrenalism including Addison's disease.....	191
	Dysfunctions of gonads.....	192
	Pancreatic endocrine disorders.....	193
	Multiple endocrine neoplasia.....	194
	Endocrine testing: Suppression and stimulation tests.....	194
	Summary/key points.....	198
	References.....	204
CHAPTER 10	Liver diseases and liver function tests.....	207
	Liver physiology.....	207
	Liver function tests and interpretations.....	209
	Jaundice: An introduction.....	211
	Congenital hyperbilirubinemia.....	212
	Hemolytic (prehepatic) jaundice.....	214
	Hepatocellular jaundice.....	214
	Chronic liver disease.....	215
	Cholestatic jaundice.....	217
	Alcohol and drug-induced liver disease.....	217
	Liver disease in pregnancy.....	218
	Liver disease in neonates and children.....	219
	Nonalcoholic fatty liver disease.....	219
	Macro liver enzymes.....	220
	Delta bilirubin.....	221
	Laboratory measurement of bilirubin and other tests.....	221
	Summary/key points.....	222
	References.....	226

CHAPTER 11	Renal function tests.....	229
	Basic functions of kidneys.....	229
	Glomerular filtration rate.....	231
	Creatinine clearances and estimated GFR.....	233
	Biochemical assessment of renal function.....	234
	Creatinine.....	234
	Urea (blood urea nitrogen) and uric acid.....	235
	Cystatin C.....	235
	Assessment of glomerular integrity.....	236
	Tests for renal tubular function.....	236
	Acute renal failure.....	236
	BUN/creatinine ratio.....	237
	Fractional excretion of sodium.....	237
	Chronic kidney disease.....	238
	Proteinuria.....	239
	Types of proteinuria.....	241
	Methods to detect proteinuria.....	242
	Nephrotic syndrome.....	243
	Nephritic syndrome.....	244
	Hematuria.....	244
	Glomerular versus nonglomerular bleeding.....	245
	Fanconi syndrome.....	246
	Renal tubular acidosis.....	246
	Renal calculi.....	246
	Laboratory measurements of creatinine and related tests.....	247
	Urine dipstick analysis.....	248
	Summary/key points.....	249
	References.....	251
CHAPTER 12	Inborn errors of metabolism.....	253
	Overview of inborn errors of metabolism.....	253
	Amino acid disorders.....	255
	Phenylketonuria.....	255
	Maple syrup urine disease (MSUD).....	256
	Other amino acid disorders.....	256
	Carbohydrate metabolism disorders.....	257
	Galactosemia.....	257
	Glycogen storage disease (GSD).....	257
	Fructose intolerance.....	257
	Lactose intolerance.....	258
	Urea cycle disorders.....	258

	Organic acid disorders (organic aciduria).....	259
	Fatty acid oxidation disorders.....	260
	Mitochondrial disorders.....	260
	Peroxisomal disorders.....	261
	Lysosomal storage disorders.....	261
	Purine or pyrimidine metabolic disorders.....	263
	Disorders of porphyrin metabolism.....	263
	Newborn screening and evaluation.....	264
	Summary/key points.....	265
	References.....	268
CHAPTER 13	Tumor markers.....	269
	Introduction to tumor markers.....	269
	Clinical uses of tumor markers and common tumor markers.....	270
	Prostate-specific antigen (PSA).....	271
	False-positive and unexpected PSA results.....	275
	Newer biomarkers of prostate cancer.....	276
	Cancer antigen 125 (carbohydrate antigen 125: CA-125).....	276
	False-positive CA-125.....	277
	Emerging biomarkers of ovarian cancer.....	277
	Cancer antigen-19-9 (carbohydrate antigen: 19-9: CA 19-9).....	278
	Alpha-fetal protein (AFP, α -fetoprotein).....	279
	False-positive AFP.....	280
	Carcinoembryonic antigen (CEA).....	281
	False-positive CEA.....	282
	β_2 -Microglobulin.....	282
	Human chorionic gonadotropin (hCG).....	283
	Causes and evaluation of persistent low level of hCG.....	283
	False-positive hCG.....	284
	CA-15-3 and HER2.....	285
	CA 72-4.....	285
	Markers for thyroid cancer.....	286
	Less commonly monitored cancer biomarkers.....	287
	Summary/key points.....	288
	References.....	292
CHAPTER 14	Therapeutic drug monitoring.....	295
	What is therapeutic drug monitoring?.....	295
	Drugs that require therapeutic drug monitoring.....	296
	Free versus total drug monitoring.....	296
	Therapeutic drug monitoring benefits.....	296
	Basic pharmacokinetics.....	297

	Effect of gender and pregnancy on drug metabolism and disposition.....	300
	Effect of age on drug metabolism and disposition.....	301
	Drug metabolism and disposition in uremia.....	302
	Drug metabolism and disposition in liver disease.....	303
	Effect of cardiovascular disease on drug metabolism and disposition.....	303
	Thyroid dysfunction and drug metabolism.....	304
	Effect of food, alcohol consumption, and smoking on drug disposition.....	304
	Therapeutic drug monitoring of various drug classes:	
	General considerations.....	305
	Preanalytical issues in therapeutic drug monitoring.....	308
	Therapeutic drug monitoring of anticonvulsants.....	309
	Therapeutic drug monitoring of cardioactive drugs.....	311
	Therapeutic drug monitoring of antiasthmatic drugs.....	312
	Therapeutic drug monitoring of antidepressants.....	312
	Therapeutic drug monitoring of immunosuppressants.....	313
	Therapeutic drug monitoring of selected antibiotics.....	314
	Therapeutic drug monitoring of antineoplastic drugs.....	315
	Therapeutic drug monitoring of antiretrovirals.....	316
	Therapeutic drug monitoring using oral fluids.....	316
	Therapeutic drug monitoring using dried blood spot.....	317
	Summary/key points.....	319
	References.....	322
CHAPTER 15	Interferences in therapeutic drug monitoring.....	325
	Methodologies used in therapeutic drug monitoring and issues of interferences.....	325
	Effect of endogenous factors on therapeutic drug monitoring.....	326
	Digoxin immunoassays: So much interference.....	327
	Interferences in analysis of antiepileptics.....	330
	Interferences in analysis of tricyclic antidepressants.....	331
	Interferences in analysis of immunosuppressants.....	332
	Interferences in analysis of antibiotics.....	333
	Interferences of paraprotein in therapeutic drug monitoring....	333
	Summary/key points.....	334
	References.....	335
CHAPTER 16	Drugs of abuse testing.....	337
	Commonly abused drugs in the United States.....	337
	Medical versus workplace drug testing.....	338

	SAMHSA versus non-SAMHSA drugs.....	340
	Detection window of various drugs in urine.....	342
	Metabolism of abused drugs/target of immunoassay antibody....	343
	Immunoassays versus confirmation.....	347
	False-positive immunoassay test results with various abused drugs.....	349
	False-negative test results.....	350
	Derivatization in GC/MS vs direct analysis using LC-MS/MS....	352
	Analytical true positive due to use of prescription drugs and other factors.....	354
	Issues of adulterated urine specimens in workplace drug testing.....	355
	Miscellaneous other issues in drugs of abuse testing.....	357
	Summary/key points.....	357
	References.....	359
CHAPTER 17	Designer drugs, date rape drugs, LSD, volatiles, magic mushroom, and peyote cactus abuse.....	361
	Negative toxicology report.....	361
	Abuse of amphetamine-like designer drugs including bath salts.....	361
	Abuse of synthetic marijuana (Spice, K2).....	364
	Designer drugs that are opioid analogs.....	367
	Meperidine and phencyclidine-like designer drugs.....	368
	Rave party drugs and date rape drugs.....	369
	LSD abuse.....	371
	Abuse of volatiles (solvents).....	372
	Magic mushroom abuse.....	373
	Peyote cactus abuse.....	375
	Summary/key points.....	376
	References.....	378
CHAPTER 18	Testing for ethyl alcohol (alcohol) and other volatiles....	381
	Alcohol use and abuse.....	381
	Health benefits of moderate drinking.....	384
	Health hazards of heavy drinking.....	385
	Metabolism of alcohol: Effect of gender.....	386
	Metabolism of ethyl alcohol: Effect of genetic factors.....	388
	Relation between whole blood alcohol and serum alcohol and legal limit of driving.....	390
	Analysis of alcohol in body fluids: Limitations and pitfalls.....	391
	Headspace gas chromatography for alcohol determination.....	393

	Breath alcohol measurement.....	394
	Biomarkers of alcohol abuse.....	396
	Methanol abuse.....	398
	Abuse of ethylene glycol and other alcohols.....	399
	Summary/key points.....	401
	References.....	404
CHAPTER 19	Common poisonings including heavy metal poisoning....	405
	Poisoning from analgesics.....	405
	Methyl salicylate poisoning.....	407
	Carbon monoxide poisoning.....	408
	Cyanide poisoning.....	409
	Overdose with tricyclic antidepressants.....	410
	Benzodiazepine and opiate overdose.....	411
	Alcohol poisoning.....	411
	Poisoning from organophosphorus and carbamate insecticides.....	412
	Lead poisoning.....	412
	Mercury poisoning.....	414
	Arsenic poisoning.....	415
	Poisoning from other metals.....	415
	Summary/key points.....	416
	References.....	418
CHAPTER 20	Pharmacogenomics.....	421
	Introduction to pharmacogenomics.....	421
	Basic pharmacogenomics.....	423
	Nomenclature.....	423
	Various metabolizer types.....	423
	Other polymorphic enzymes that metabolize drugs.....	424
	Polymorphism of transporter proteins and receptors.....	425
	Pharmacogenomics and warfarin therapy.....	425
	Pharmacogenomics of selected anticancer drugs.....	426
	Pharmacogenomics of selected opioid drugs.....	427
	Pharmacogenomics of selected psychoactive drugs.....	428
	Pharmacogenomics of miscellaneous other drugs.....	428
	Methods for pharmacogenomics testing.....	429
	Summary/key points.....	429
	References.....	430
CHAPTER 21	Point-of-care testing.....	433
	Introduction to point-of-care testing.....	433
	POCT devices: Methodologies.....	434
	Glucose measurement using POCT.....	436

	Measuring multiple analytes using POCT.....	437
	Cardiac markers.....	437
	Pregnancy test.....	438
	Coagulation POCT.....	438
	Infectious disease.....	439
	POCT for drugs of abuse.....	439
	Important issues with POCT devices.....	441
	Key points.....	442
	References.....	443
CHAPTER 22	Biotin interferences with immunoassays.....	445
	Biotin.....	445
	Serum biotin levels.....	445
	Biotin interference.....	446
	FDA safety communication on biotin.....	448
	Biotin interferences in thyroid function tests.....	448
	Biotin falsely lower parathyroid hormone level.....	449
	Biotin interferes with cardiac function tests.....	449
	Biotin interferences in multiple immunoassays.....	450
	Diagnostic companies using biotin-based assays: A review.....	451
	Approaches to overcome biotin interference.....	451
	Key points.....	452
	References.....	454
CHAPTER 23	Hemoglobinopathies and thalassemia.....	457
	Introduction.....	457
	Hemoglobin structure and synthesis.....	457
	Introduction to hemoglobinopathies.....	459
	Alpha-thalassemia.....	461
	Beta-thalassemia.....	463
	Delta-thalassemia.....	464
	Sickle cell disease.....	466
	Hereditary persistence of fetal hemoglobin (HPFH).....	467
	Other hemoglobin variants.....	468
	Laboratory investigation of hemoglobinopathies.....	471
	Gel electrophoresis.....	472
	Interpretation of alkaline and acid gels.....	472
	High-performance liquid chromatography (HPLC).....	474
	Capillary electrophoresis.....	475
	Reporting normal hemoglobin pattern.....	476
	Diagnostics tips for thalassemia, sickle cell disease, and other hemoglobinopathies.....	476
	Apparent hemoglobinopathy after blood transfusion.....	480

	Universal newborn screening.....	480
	Key points.....	483
	References.....	486
CHAPTER 24	Protein electrophoresis and immunofixation.....	489
	Introduction.....	489
	Serum protein electrophoresis.....	491
	Urine electrophoresis.....	496
	Immunofixation studies.....	497
	Capillary zone electrophoresis.....	499
	Free light chain assay.....	500
	Mass spectrometry in diagnosis of multiple myeloma.....	501
	Paraprotein interferences in clinical laboratory tests.....	502
	Other plasma cell disorders.....	502
	Morphology of plasma cells in myeloma.....	504
	Cerebrospinal fluid electrophoresis.....	504
	Summary/key points.....	506
	References.....	510
CHAPTER 25	Human immunodeficiency virus (HIV)	
	and hepatitis testing.....	513
	Human immunodeficiency virus testing.....	513
	Window period in HIV infection.....	513
	Standard HIV testing.....	516
	Testing algorithm.....	517
	Rapid HIV antibody testing.....	518
	Confirmatory HIV test.....	518
	HIV viral load test and related assays.....	519
	Introduction to hepatitis testing.....	520
	Testing for hepatitis B.....	522
	Testing for hepatitis C.....	525
	Immunization and false-positive HIV and hepatitis testing.....	528
	Testing for Epstein-Bar virus.....	528
	Summary/key points.....	529
	References.....	532
CHAPTER 26	Autoimmunity, complement, and immunodeficiency.....	535
	Introduction to immune system and complement.....	535
	T lymphocytes and cell-mediated immunity.....	536
	B cells and humoral immunity.....	537
	Pathways of complement activation.....	537
	Immunodeficiency.....	539
	B-cell defect.....	539

T-cell defects.....	540
Both B- and T-cell defects.....	540
Major histocompatibility complex.....	542
HLA testing.....	543
Transplant rejection.....	544
Graft-versus-host disease.....	545
Autoimmune serology.....	546
Antineutrophil cytoplasmic antibodies.....	549
Hypersensitivity reactions and hypersensitivity-mediated disorders.....	550
Summary/key points.....	551
References.....	556
CHAPTER 27 Effect of herbal supplements on clinical laboratory test results.....	557
Use of herbal remedies in the United States.....	557
How herbal remedies affect clinical laboratory test results.....	558
Liver damage as reflected by abnormal liver function test after using certain herbals.....	558
Kidney damage and herbal supplements.....	560
Kelp and thyroid function.....	561
Miscellaneous abnormal test results due to use of certain herbals.....	562
Drug-herb interactions.....	562
Herbs adulterated with western drugs and herbs contaminated with heavy metals.....	565
Grapefruit juice-drug interaction.....	565
Summary/key points.....	566
References.....	568

INDEX.....	571
-------------------	------------